Modified immune cells tested as potential reset for devastating autoimmune disease
NCT ID NCT06792344
Summary
This early-stage study is testing whether a therapy called CAR-T, which reprograms a patient's own immune cells, can help people with severe systemic sclerosis (scleroderma) that hasn't responded to other treatments. The goal is to see if this approach is safe and can reduce skin thickening and organ damage caused by the disease. The trial will enroll 12 participants, including children as young as 5 and adults, who have not improved with standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 0571, China
Contact
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310053, Christmas Island
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.